Zakrzewski Joseph S 4

What Happened

• Joseph S. Zakrzewski, a director of AN2 Therapeutics (ANTX), received repriced option awards on March 19, 2026 and simultaneously had the prior options canceled. The transactions show grants (A) of 99,999; 10,362; and 23,742 derivative shares (total 134,103) and matching dispositions (D) of the same amounts to the issuer the same day. These are derivative transactions (options), not open‑market purchases or sales, and no cash sale/purchase of common stock is reported.

Key Details

• Transaction date: March 19, 2026; Form 4 filed March 23, 2026 (timely).
• Options granted (repriced): 99,999; 10,362; 23,742 (total 134,103 derivative shares).
• Options canceled/disposed to issuer: identical amounts canceled the same day.
• Exercise price of the repriced option(s): $3.91 per share (equal to the issuer’s closing price on the repricing date). Footnote: the $3.91 price will revert to the original exercise price if the repriced option is exercised or the reporting person’s service ends prior to the “Premium End Date.”
• Premium End Date: earliest of (i) Sept 19, 2027, (ii) a change in control, or (iii) the reporting person’s death or disability.
• Vesting: the option(s) are fully vested.
• Filing timeliness: filed within the SEC deadline (not indicated as late).
• Shares owned after the transaction: not specified in the provided filing excerpt.

Context

• These entries reflect option repricing and replacement rather than a buy or sell of common stock; they should be read as a change to the terms of existing equity awards. Because the options are fully vested and were repriced to $3.91 (with conditions that could revert the price), this is an administrative equity‑compensation action approved by the board rather than a market trade.